Johnson & Johnson preferred over Kenvue for long-term dividend investors
A Motley Fool analysis favours Johnson & Johnson’s dividend record and diversified operations, while warning that Kenvue’s higher yield is weighed down by slower growth and acquisition uncertainty.
Johnson & Johnson has been favoured over Kenvue as a long-term, buy-and-hold dividend investment in an analysis published by The Motley Fool. The comparison weighs J&J’s dividend history and diversified pharmaceutical and medical-technology business against Kenvue’s higher yield and consumer-health brands.
J&J is reported to have increased its dividend for 64 consecutive years. Its annual payout is listed at US$5.36 per share, equivalent to a forward yield of about 2%. The company’s post-separation operations focus on pharmaceuticals and medical technology, including oncology, immunology and surgical devices.
The analysis also identifies significant risks. J&J faces ongoing talc-related litigation, including a proposed US$5.5 billion settlement covering ovarian-cancer claims that requires 95% participation. Mesothelioma cases are continuing individually, while J&J had about US$3.7 billion reserved for talc liabilities as of the second quarter of 2026. The proposed settlement and other legal outcomes remain unresolved.
Kenvue pays US$0.84 per share annually and has a stated forward yield of 4.71%. It owns mature consumer brands including Tylenol, Band-Aid and Listerine, but the analysis describes its growth prospects as slower. Kenvue trades at about 21 times earnings, compared with roughly 31 times for J&J.
A further uncertainty is Kimberly-Clark’s proposed acquisition of Kenvue. The companies agreed in November 2025 to a cash-and-stock transaction valued at about US$48.7 billion, according to the article. The deal could affect Kenvue’s future as a standalone dividend stock and leaves the terms of the combined company’s dividend unresolved.
The analysis concludes that J&J’s dividend record, cash flow and business diversification outweigh its legal risks, making it the preferred choice for buy-and-hold investors “for now”. It reports a consensus “Moderate Buy” rating for J&J and “Hold” for Kenvue, though the figures and investment case are time-sensitive.
